Synopsis
Distinguish genitourinary syndrome of menopause from infection and urological disease, prescribe low-dose vaginal oestrogen safely, and place it correctly within the NICE recurrent-UTI prevention pathway.
- Genitourinary syndrome of menopause can cause dryness, irritation, dyspareunia, urinary urgency, frequency and dysuria, but infection, haematuria and malignancy still require independent assessment.
- Confirm recurrent UTI as at least two episodes in six months or three in twelve months; chronic culture-negative discomfort is not recurrent bacterial infection.
- Offer low-dose vaginal oestrogen for menopausal genitourinary symptoms, including to people already using systemic HRT; choose cream, gel, tablet, pessary or ring through shared decision making.
- Explain that absorption is mainly local, serious adverse effects are very rare and symptoms commonly return after stopping, so treatment can be continued and reviewed rather than limited to an arbitrary short course.
- Low-dose vaginal oestrogen with postmenopausal-range systemic exposure does not routinely require added systemic progestogen, but any unexplained bleeding must be investigated.
- For recurrent UTI around or after menopause, NICE says to consider vaginal oestrogen when behavioural and personal-hygiene measures are ineffective or inappropriate.
- Do not offer systemic HRT specifically to prevent recurrent UTI, and do not use vaginal oestrogen to treat an acute bacterial infection.
- A common estradiol-tablet regimen is 10 micrograms vaginally once daily for two weeks, then twice weekly; cream doses are product specific and require the matching applicator instruction.
- After breast cancer, start with non-hormonal moisturisers or lubricants; consider vaginal oestrogen for persistent symptoms, and work with the breast specialist when aromatase-inhibitor therapy is current.
Key red flags
Fever, rigors, flank pain, vomiting, hypotension or confusion with urinary symptoms suggests pyelonephritis or urosepsis and requires same-day treatment.
Visible haematuria, persistent sterile pyuria, weight loss or a bladder or pelvic mass requires investigation beyond genitourinary syndrome of menopause.
Postmenopausal bleeding, blood-stained discharge, a suspicious cervix, vulval ulcer or focal induration needs a dedicated gynaecological cancer pathway.
Acute retention, hydronephrosis, recurrent upper-tract infection or deteriorating renal function warrants prompt urological assessment.
New neurological weakness, saddle sensory change or bowel dysfunction with altered bladder control requires emergency assessment for spinal compression.
Investigation priorities
Confirm infection during a compatible urinary episode and identify resistance that changes acute or preventive treatment.
Management branches
Dryness, irritation, dyspareunia or culture-negative urinary discomfort fits genitourinary syndrome of menopause.
- Exclude bleeding, focal lesions, infection and urinary red flags, examining when the result will alter management.
- Offer vaginal oestrogen and choose the formulation collaboratively, adding regular moisturiser and activity-specific lubricant when useful.
- Review response, application technique, irritation and bleeding; continue effective treatment because recurrence after stopping is common.